On June 24, we reached a new milestone in the fight against cystic fibrosis. Phase 3 clinical trials of Kalydeco™ in combination with VX-809 for people with two copies of the F508del mutation of cystic fibrosis showed significant improvements in lung function and other key measures of the disease. This marks an important milestone for nearly 50 percent of people with cystic fibrosis. We want to thank each of you. Without you, this kind of immense progress would not be possible. Our commitment to cure CF is stronger than ever, and we will not rest until a cure is found for all people with CF.
